Status:
COMPLETED
DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.
Lead Sponsor:
Universidad Autonoma de San Luis Potosí
Conditions:
Melasma
Eligibility:
FEMALE
18-50 years
Phase:
EARLY_PHASE1
Brief Summary
BACKGROUND: Malar melasma has a chronic and recurrent character that may be related with epigenetic changes.
Detailed Description
OBJECTIVE: Recognize the DNA methylation status of the malar melasma and perilesional skin, and its change after treatment with 50 SPF sunscreen (S), 4% niacinamide (N), or 0.025% retinoic acid (RA). ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of malar melasma by a specialist. No previous treatment at the beginning of the study.
Exclusion
- Use of medications associated with the development of melasma. Pregnant or lactating patients. Presence of concomitant diseases associated with the development of melasma. or other facial hyperpigmentations (thyroid, liver).
- Have received treatment in the last 2 months. Regular use of sunscreen.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT03392623
Start Date
January 1 2015
End Date
December 1 2016
Last Update
January 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.